Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase III trial of adjuvant chemotherapy with gemcitabine vs S-1 in patients with resected pancreatic cancer

X
Trial Profile

Randomized phase III trial of adjuvant chemotherapy with gemcitabine vs S-1 in patients with resected pancreatic cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
  • Indications Carcinoma; Ductal carcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2020 Results of a pooled analysis from four phase III trials: CONKO-001, JASPAC-01, ESPAC-4 and PRODIGE assessing prolongation of average survival time, prolongation of average event free time and time lived without an event presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 01 Feb 2020 Results of a retrospective biomarker study published in the Cancer Science.
    • 22 Feb 2018 Results (n=354) assessing health-related quality of life with of S-1 versus gemcitabine in patients with pancreatic cancer published in the European Journal of Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top